175 related articles for article (PubMed ID: 30775841)
1. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.
Peitsch WK
J Dtsch Dermatol Ges; 2019 Mar; 17(3):330-332. PubMed ID: 30775841
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
Takama H; Shibata T; Ando Y; Yanagishita T; Ohshima Y; Akiyama M; Watanabe D
Eur J Dermatol; 2020 Apr; 30(2):188-190. PubMed ID: 32538362
[No Abstract] [Full Text] [Related]
4. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.
Fattore D; Annunziata MC; Panariello L; Marasca C; Fabbrocini G
Eur J Cancer; 2019 Mar; 110():107-109. PubMed ID: 30785013
[No Abstract] [Full Text] [Related]
5. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
6. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
[No Abstract] [Full Text] [Related]
7. Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
Vico-Alonso C; Sánchez-Velázquez A; Pinilla-Martin B; Andrés-Lencina JJ; Aragón-Miguel R; Calleja-Algarra A; Rivera-Díaz R
Int J Dermatol; 2020 Apr; 59(4):e102-e103. PubMed ID: 31347142
[No Abstract] [Full Text] [Related]
8. Apremilast for a psoriasis patient with HIV and hepatitis C.
Reddy SP; Shah VV; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e481-e482. PubMed ID: 28449227
[No Abstract] [Full Text] [Related]
9. One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Lanna C; Mazzilli S; Zangrilli A; Bianchi L; Campione E
Dermatol Ther; 2019 Nov; 32(6):e13089. PubMed ID: 31577864
[TBL] [Abstract][Full Text] [Related]
10. Apremilast, beyond psoriasis as a therapeutic target.
Ruiz-Villaverde R; Bueno-Rodriguez A; Tercedor-Sánchez J
Med Clin (Barc); 2017 Jul; 149(1):42-43. PubMed ID: 28242122
[No Abstract] [Full Text] [Related]
11. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.
Sacchelli L; Patrizi A; Loi C; Bardazzi F
Clin Exp Dermatol; 2019 Oct; 44(7):e243-e244. PubMed ID: 31055844
[No Abstract] [Full Text] [Related]
12. Maintenance rituximab in mantle-cell lymphoma.
Burki TK
Lancet Oncol; 2017 Nov; 18(11):e647. PubMed ID: 28988912
[No Abstract] [Full Text] [Related]
13. Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.
Mori S; Patel RD; Ahmad S; Varela J; Smith T; Altoos R; Shen Q; Goldstein SC; Persky DO
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):e93-e97. PubMed ID: 30559058
[No Abstract] [Full Text] [Related]
14. A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast.
Waki Y; Kamiya K; Komine M; Maekawa T; Murata S; Ishii N; Hashimoto T; Ohtsuki M
Eur J Dermatol; 2018 Jun; 28(3):413-414. PubMed ID: 29619999
[No Abstract] [Full Text] [Related]
15. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.
Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
J Am Acad Dermatol; 2018 Nov; 79(5):953-956. PubMed ID: 29730366
[No Abstract] [Full Text] [Related]
16. Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment.
Muñoz-Santos C; Sola-Ortigosa J; Guilabert A
Clin Exp Dermatol; 2018 Jul; 43(5):606-607. PubMed ID: 29453771
[No Abstract] [Full Text] [Related]
17. Rituximab-associated colitis.
Barreiro Alonso E; Álvarez Álvarez A; Tojo González R; de la Coba Ortiz C
Gastroenterol Hepatol; 2019 Apr; 42(4):251-252. PubMed ID: 29884483
[No Abstract] [Full Text] [Related]
18. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
19. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
[No Abstract] [Full Text] [Related]
20. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
Magdaleno-Tapial J; Valenzuela-Oñate C; Ortiz-Salvador JM; Subiabre-Ferrer D; Hernández-Bel P
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
